Liangyihui

Liangyihui, legally registered as Suzhou Liangyihui Network Technology Co., Ltd., is a digital healthcare company established in March 2015 with a specific focus on the oncology sector in China. The company was co-founded by Jue Wang, who currently serves as the Chairman and General Manager. The founding team possesses extensive experience in both the pharmaceutical and internet industries, positioning the company at the intersection of healthcare and technology. Liangyihui has successfully secured significant financial backing through multiple funding rounds, including a Series C+ round in October 2021, attracting investments from prominent firms such as Shunwei Capital, Tencent Investment, Qiming Venture Partners, and Detong Capital.

The firm operates a comprehensive digital platform designed to address information asymmetry within the cancer treatment landscape. Its business model centers on connecting key stakeholders: pharmaceutical companies, physicians, hospitals, and patients. For healthcare professionals, Liangyihui offers a platform for continuing education, access to the latest research, case studies, and opportunities for professional branding. For patients, it provides access to credible information, expert consultations, and support services. Revenue is generated by providing digital marketing and service solutions to pharmaceutical companies, helping them to effectively reach and educate their target audience of oncology professionals and patients. The company reports that it has achieved profitability.

Liangyihui's service portfolio is delivered through a matrix of digital products, including the "Oncology Doctor" App, "Oncology Information" and "Patient Guide" WeChat public accounts, and an internet hospital platform. These tools aim to digitize and streamline traditionally offline activities like medical education, patient services, and pharmaceutical marketing. The platform has amassed a substantial user base, reportedly including nearly 200,000 oncology doctors and 300,000 patients. In a move to further leverage its data and user network, the company initiated the development of a large AI model in February 2024. This strategic initiative is intended to enhance its service offerings and create more efficient solutions for clinical management and patient care within the oncology field.

Keywords: oncology platform, digital health China, cancer care, medical information, physician education, patient support, pharmaceutical marketing, health-tech, online healthcare, oncology data, cancer treatment information, digital therapeutics, med-tech, Tencent investment, Qiming Venture Partners, Shunwei Capital, Jue Wang, tumor information, online doctor community, patient management, clinical trial support